secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2026-07-02T20:30:21+00:00
Accession:  0001213900-26-075013
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies enters $10M convertible note financing with Leonite Fund; appoints Dr. Craig Eagle to board
--------------------------------------------------------------------------------

- Enters securities purchase agreement for up to $10M senior secured convertible note with Leonite Fund I, LP; first tranche of $1.6M expected July 2, 2026.
- Note bears 9% interest, matures 9 months per tranche (max 24 months); conversion price $2.05/share; warrant to buy 1.75M shares at $2.85 through 2031.
- Director Karim Galzahr resigns effective June 1, 2026; Dr. Craig Eagle appointed to fill vacancy, currently serves as Chief Medical Advisor.
- Proceeds to fund clinical development, regulatory activities, and working capital.
- Note secured by substantially all assets (excl. IP); includes negative covenants, anti-dilution adjustments, and 4.99% beneficial ownership limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390026075013/0001213900-26-075013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390026075013/ea0296868-8k_ostherapies.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-075013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer